NEW YORK – The UK's National Institute for Health and Care Excellence (NICE) on Friday recommended that the National Health Service make AstraZeneca's AKT pathway inhibitor Truqap (capivasertib) with ...

Mutations in the oncogene KRAS are widespread in several human cancers, including pancreatic ductal adenocarcinomas (92%), colorectal carcinomas (49%) and lung adenocarcinomas (35%). These mutations ...

Scientists have discovered a new protein pathway involved in neurodegeneration by studying “mini-brain” organoids made from ...

Researchers sought to evaluate differences in ctDNA profiles, use of targeted treatments, and overall survival between Black and White patients with metastatic breast cancer.

The biomarker analysis found patients with certain mutations in the PI3K/AKT/mTOR pathway and MAPK pathway may be resistant to Truqap.

Vividion Therapeutics, Inc. (Vividion) today announced that the first patient has been dosed in a Phase I clinical trial evaluating VVD-159642, an investigational oral inhibitor designed to target RAS ...

Aspirin use in patients with PIK3CA-mutated colorectal cancer reduces recurrence risk by over 50%. | Drug Discovery And Development ...

WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA), a biopharmaceutical company focused on developing treatments for rare ...

Good afternoon, ladies and gentlemen, and welcome to the Celcuity fourth quarter and full year 2024 financial results webcast conference call. (Operator Instructions) I would now like to turn the ...

Q4 2024 Earnings Call Transcript March 31, 2025 Celcuity Inc. misses on earnings expectations. Reported EPS is $-0.85 EPS, ...

A fireside chat at the 24 th Annual Needham Virtual Healthcare Conference at 11:00 a.m. ET on Thursday, April 10, 2025. A live webcast will be available using this weblink: ...

Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or "the Company"), an oncology-focused drug development company, today announced the sale of all intellectual property and trademarks rights to ...